文献速递白血病

抑制PI3K/AKT/mTOR通路联合全反式维甲酸治疗通过抑制MYC在急性髓系白血病中获得治疗收益

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2022-04-25

本研究探讨PI3K/AKT/mTOR(PAM)通路小分子抑制剂联合全反式维甲酸(ATRA)靶向多种急性髓系白血病(AML)亚型的策略。结果显示ATRA联合PI3K抑制剂ZSTK474、mTOR抑制剂WYE132或PI3K/mTOR抑制剂BEZ235(dactolisib)大幅降低原癌基因MYC蛋白水平;BEZ235联合ATRA几乎完全清除细胞MYC、引起G1期阻滞、丧失克隆能力并终末粒系分化。PAM抑制剂与ATRA通过独立机制靶向MYC:PAM抑制经糖原合成酶激酶3β致MYC苏氨酸58磷酸化后降解,ATRA则降低其表达。

要点

  • ATRA联合PI3K、mTOR或PI3K/mTOR抑制剂大幅降低AML细胞MYC蛋白水平。
  • BEZ235联合ATRA几乎完全清除细胞MYC,导致G1期阻滞、克隆能力丧失和终末粒系分化。
  • PAM抑制剂经GSK3β使MYC苏氨酸58磷酸化后降解,ATRA则降低MYC表达,机制独立。

核心结论

  • 联合已知药物协同降低异常MYC水平,可有效阻断多种AML亚型增殖并使其分化。

研究设计与样本

  • 体外研究,测试PAM通路小分子抑制剂联合ATRA靶向多种AML亚型。

主要发现

  • ATRA联合PI3K抑制剂ZSTK474、mTOR抑制剂WYE132或PI3K/mTOR抑制剂BEZ235(dactolisib)大幅降低MYC蛋白水平。
  • BEZ235联合ATRA几乎完全清除细胞MYC,引起G1期阻滞、克隆能力丧失和终末粒系分化。
  • PAM抑制剂经糖原合成酶激酶3β使MYC苏氨酸58磷酸化后降解,ATRA则降低MYC表达,二者机制独立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling, contribute to enhanced proliferation and the differentiation blockade of immature myeloid cells in acute myeloid leukaemia (AML). Inhibition of the PAM pathway was shown to affect especially mixed-lineage leukaemia-rearranged AML. Here, we sought to test a combined strategy using small molecule inhibitors against members of the PAM signalling pathway in conjunction with all-trans retinoic acid (ATRA) to target a larger group of different AML subtypes. We find that ATRA treatment in combination with inhibition of PI3K (ZSTK474), mTOR (WYE132) or PI3K/mTOR (BEZ235, dactolisib) drastically reduces protein levels of the proto-oncogene MYC. In combination with BEZ235, ATRA treatment led to almost complete eradication of cellular MYC, G1 arrest, loss of clonal capacity and terminal granulocytic differentiation. We demonstrate that PAM inhibitor/ATRA treatment targets MYC via independent mechanisms. While inhibition of the PAM pathway causes MYC phosphorylation at threonine 58 via glycogen synthase kinase 3 beta and subsequent degradation, ATRA reduces its expression. Here, we present an approach using a combination of known drugs to synergistically reduce aberrant MYC levels, thereby effectively blocking proliferation and enabling differentiation in various AML subtypes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Stengel S, Petrie KR, Sbirkov Y, et al. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia. Br J Haematol. 2022. PMID: 35468223. doi:10.1111/bjh.18187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。